ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Skeletal muscle reprogramming of metabolic, ribosomal and developmental pathways contributes to Roux-en-Y gastric bypass-induced adaptation in women.EBioMedicine · 2026Article
- Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Proteomics signatures associated with cognitive trajectories: evidence from the English Longitudinal Study of Ageing.medRxiv : the preprint server for health sciences · 2026Article
- Associations between cognitive frailty and circulating cardiovascular biomarkers in a memory clinic cohort.GeroScience · 2026Article
- Article
- Association of Atrial Electrophysiological Abnormalities With Cognitive Decline and Cerebrovascular Disease.Journal of the American Heart Association · 2026Article
- Transcriptomic signatures as biomarkers for the progression of mild cognitive impairment.Frontiers in aging neuroscience · 2026Article
- Comparison of the additive value of blood-based and retinal biomarkers to clinical features in predicting cognitive decline.Communications medicine · 2025Article
- Temporal Validation of a Plasma Diagnosis Approach for Early Alzheimer Disease Diagnosis in a Cognitive Disorder Unit.Journal of personalized medicine · 2025Article
- From Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory.Biomedicines · 2025Article
- Spotlight on Alzheimer's disease and related dementias research in East Asia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort.Brain communications · 2025Article
- U-shaped association of resting heart rate with cognitive decline.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionThe prognostic utility of plasma proteomics for cognitive decline and dementia in a Southeast Asian population characterized by high cerebrovascular disease (CeVD) burden is underexplored.
methodsWe examined this in a Singaporean memory clinic cohort of 528 subjects (n = 300, CeVD; n = 167, incident cognitive decline) followed-up for 4 years.
resultsOf 1441 plasma proteins surveyed, a 12-protein signature significantly predicted cognitive decline (q-value < .05). Sixteen diverse biological processes were implicated in cognitive decline. Ten proteins independently predicted incident dementia (q-value < .05). A unified prediction model combining plasma proteins with clinical risk factors increased the area under the curve for outcome prediction from 0.62 to 0.85. External validation in the cerebrospinal fluid proteome of an independent Caucasian cohort replicated four of the significantly predictive plasma markers for cognitive decline namely: GFAP, NEFL, AREG, and PPY. DISCUSSION: The prognostic proteins prioritized in our study provide robust signals in two different biological matrices, representing potential mechanistic targets for dementia and cognitive decline. HIGHLIGHTS: A total of 1441 plasma proteins were profiled in a Singaporean memory clinic cohort. We report prognostic plasma protein signatures for cognitive decline and dementia. External validation was performed in the cerebrospinal fluid proteome of a Caucasian cohort. A concordant proteomic signature was identified across both biofluids and cohorts. Further studies are needed to explore the therapeutic implications of these proteins for dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.